SCHEMBL22015757

SCHEMBL22015757

N#Cc1cc2cnc(Nc3ccc(N4CCNCC4)cc3)nc2n(C2CCCC2)c1=O

nearest known ligand 0.81

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CDK4 P11802 20/20 0.81
CCND1 P24385 19/20 0.81
CCNA2 P20248 15/20 0.81
CDK2 P24941 15/20 0.81
FGFR1 P11362 13/20 0.81
CCNE1 P24864 4/20 0.81
CDK1 P06493 3/20 0.81
CCNB1 P14635 3/20 0.81
CDK6 Q00534 2/20 0.81
PIK3CD O00329 1/20 0.81
PRKAB2 O43741 1/20 0.81
NUAK1 O60285 1/20 0.81
CCNT1 O60563 1/20 0.81
ABL1 P00519 1/20 0.81
FYN P06241 1/20 0.81
CSF1R P07333 1/20 0.81
RET P07949 1/20 0.81
PDGFRB P09619 1/20 0.81
MARK3 P27448 1/20 0.81
FLT3 P36888 1/20 0.81

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
Trifluoroacetic Acid SCHEMBL28583784 0.93 CDK4 (0.71) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL10050960 0.90 CDK4 (0.82) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL22164899 0.90 CDK4 (0.66) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL22171164 0.90 CDK4 (0.77) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL22860031 0.90 CDK4 (0.84) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL29507978 0.90 CDK4 (0.84) CDK4CCND1CCNA2CDK2FGFR1
Narazaciclib SCHEMBL30418763 0.90 CDK4 (1.00) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL14954977 0.90 CDK4 (0.81) CDK4CCND1CCNA2CDK2FGFR1
Narazaciclib SCHEMBL10050883 0.90 CDK4 (1.00) CDK4CCND1CCNA2CDK2FGFR1
SCHEMBL24618846 0.89 CDK4 (0.92) CDK4CCND1CCNA2CDK2FGFR1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20220220103-A1 CYCLIN-DEPENDENT KINASE INHIBITORS SPV THERAPEUTICS INC. 2022-07-14 US disclosed
US-20220002293-A1 8-CYCLOPENTYL-7-OXO-2-(4-PIPERAZIN-1-YL-PHENYLAMINO)-7, 8-DIHYDRO-PYRIDO [2,3-D]PYRIMIDINE-6-CARBONITRILE AND USES THEREOF IN TREATING PROLIFERATIVE DISORDERS ONCONOVA THERAPEUTICS, INC. (US) 2022-01-06 US disclosed
CN-112969463-A 8-cyclopentyl-7-oxo-2- (4-piperazin-1-yl-phenylamino) -7, 8-dihydro-pyrido [2,3-D ] pyrimidine-6-carbonitrile and its use in the treatment of proliferative diseases 安哥洛华治疗公司 2021-06-15 CN disclosed
CN-112969463-A 8-cyclopentyl-7-oxo-2- (4-piperazin-1-yl-phenylamino) -7, 8-dihydro-pyrido [2,3-D ] pyrimidine-6-carbonitrile and its use in the treatment of proliferative diseases 安哥洛华治疗公司 2021-06-15 CN disclosed
WO-2020140053-A1 CYCLIN-DEPENDENT KINASE INHIBITORS SPV THERAPEUTICS INC. (US) 2020-07-02 WO disclosed
WO-2020101638-A1 8-CYCLOPENTYL-7-OXO-2-(4-PIPERAZIN-1-YL-PHENYLAMINO)-7, 8-DIHYDRO-PYRIDO [2,3-D]PYRIMIDINE-6-CARBONITRILE AND USES THEREOF IN TREATING PROLIFERATIVE DISORDERS ONCONOVA THERAPEUTICS, INC. (US) 2020-05-22 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20220002293-A1 8-CYCLOPENTYL-7-OXO-2-(4-PIPERAZIN-1-YL-PHENYLAMINO)-7, 8-DIHYDRO-PYRIDO [2,3-D]PYRIMIDINE-6-CARBONITRILE AND USES THEREOF IN TREATING PROLIFERATIVE DISORDERS DPYD, POLN, DCK CDK4 8/4885CCND1 211/4885CCNA2 37/4885
US-20220220103-A1 CYCLIN-DEPENDENT KINASE INHIBITORS CDK2, CDK1, CCNK CDK4 9/4885CCND1 51/4885CCNA2 34/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.